Time slot's time in Taipei (GMT+8)
2025/11/21 12:10-13:00 Room 101 CD
- Lunch Symposium-台灣禮來股份有限公司 Eli Lilly and Company (Taiwan)
台灣禮來股份有限公司 Eli Lilly and Company (Taiwan)
- Time
- Topic
- Speaker
- Moderator
- 12:10-13:00
-
From trial to clinic:
1.Practical Aspects of Kisunla Treatment: Dosing, Length of Treatment and MRI Monitoring Guidance
2.Overview of Kisunla and TRAILBLAZER-ALZ2 Study Results and real world experience sharing - Speaker:
Yen-Siang Huang
(Taiwan)
- Moderator:
Ta-Fu Chen
(Taiwan)
- Yen-Siang Huang
- Dr.
-
Section Chief of General Neurology Division, Department of Neurology, Far-Eastern Memorial Hospital
E-mail：huang.eason@gmail.com
Executive Summary：
Dr. Yen-Siang (Eason) Huang is the Section Chief of General Neurology at Far Eastern Memorial Hospital, where he leads inpatient and outpatient care across dementia, cerebrovascular disease, neurophysiology, and general neurological disorders. A graduate of the National Defense Medical Center, Dr. Huang trained in neurology at National Taiwan University Hospital, later serving there as a part-time attending. He broadened his research perspective as a visiting scientist at the Houston Methodist Research and Neurological Institutes. In addition to his clinical leadership, he contributes to medical education as an adjunct lecturer and cross-appointed instructor, including collaborations with Fu Jen Catholic University and Yuan Ze University. Dr. Huang’s current work emphasizes integrated stroke systems of care and practical strategies for brain health and dementia prevention, alongside compassionate, evidence-based treatment for complex neurological conditions. Please join me in welcoming Dr. Yen-Siang Huang.
Dr. Yen-Siang (Eason) Huang is the Section Chief of General Neurology at Far Eastern Memorial Hospital, where he leads inpatient and outpatient care across dementia, cerebrovascular disease, neurophysiology, and general neurological disorders. A graduate of the National Defense Medical Center, Dr. Huang trained in neurology at National Taiwan University Hospital, later serving there as a part-time attending. He broadened his research perspective as a visiting scientist at the Houston Methodist Research and Neurological Institutes. In addition to his clinical leadership, he contributes to medical education as an adjunct lecturer and cross-appointed instructor, including collaborations with Fu Jen Catholic University and Yuan Ze University. Dr. Huang’s current work emphasizes integrated stroke systems of care and practical strategies for brain health and dementia prevention, alongside compassionate, evidence-based treatment for complex neurological conditions. Please join me in welcoming Dr. Yen-Siang Huang.
Lecture Abstract：
Dr. Yen-Siang Huang will review Kisunla (donanemab) clinical evidence with a practical, clinic-first lens. He will outline the TRAILBLAZER-ALZ 2 (TB2) study design, including amyloid and tau eligibility, dosing/discontinuation rules, and key stratifications, then profile enrolled populations by age, disease stage, APOE ε4 status, and comorbidity. Efficacy will focus on iADRS and CDR-SB trajectories, time to clinical progression, and biomarker dynamics (amyloid PET and plasma/CSF signals). Safety will center on ARIA risk, monitoring algorithms, and mitigation in higher-risk subgroups. Dr. Huang will bridge trials to practice with emerging real-world experience, discussing patient selection, infusion/logistics pathways, payer and imaging readiness, and outcome tracking. He will also interpret Taiwan’s label and reimbursement evolution, highlighting how it expands treatment access for lower-risk patients. Finally, he will argue why donanemab represents a generational shift—from purely symptomatic management toward disease-modifying therapy—for MCI and mild Alzheimer’s disease, and share case vignettes and implementation tips.
Dr. Yen-Siang Huang will review Kisunla (donanemab) clinical evidence with a practical, clinic-first lens. He will outline the TRAILBLAZER-ALZ 2 (TB2) study design, including amyloid and tau eligibility, dosing/discontinuation rules, and key stratifications, then profile enrolled populations by age, disease stage, APOE ε4 status, and comorbidity. Efficacy will focus on iADRS and CDR-SB trajectories, time to clinical progression, and biomarker dynamics (amyloid PET and plasma/CSF signals). Safety will center on ARIA risk, monitoring algorithms, and mitigation in higher-risk subgroups. Dr. Huang will bridge trials to practice with emerging real-world experience, discussing patient selection, infusion/logistics pathways, payer and imaging readiness, and outcome tracking. He will also interpret Taiwan’s label and reimbursement evolution, highlighting how it expands treatment access for lower-risk patients. Finally, he will argue why donanemab represents a generational shift—from purely symptomatic management toward disease-modifying therapy—for MCI and mild Alzheimer’s disease, and share case vignettes and implementation tips.
